Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 57 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )
Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )
Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	NVrZWY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\QN5BKSzVyPUCuNFAxOjh5IN88US=>	MXnTRW5ITVJ?
LC-2-ad	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMECwN\|E4KM7:TR?=	MWTTRW5ITVJ?
RL95-2	M4\1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vrWmlEPTB;MD6wNFA3PjhizszN	NUXsSXVbW0GQR1XS
MZ1-PC	NX3Hcpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXoTWM2OD1yLkCwNFczQSEQvF2=	MlXxV2FPT0WU
TE-8	M4PCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXjOWR1UUN3ME2wMlAxOTF5IN88US=>	NIn3eYFUSU6JRWK=
SW954	NWH6VnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;WWYJ3UUN3ME2wMlAxOTF7IN88US=>	M2Lle3NCVkeHUh?=
TE-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn35TWM2OD1yLkCwNVI{KM7:TR?=	MVHTRW5ITVJ?
PSN1	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnMR4hqUUN3ME2wMlAxOTNizszN	MXfTRW5ITVJ?
MOLT-4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHCTWM2OD1yLkCwNVQ6KM7:TR?=	NEn3eYdUSU6JRWK=
697	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\UU3F4UUN3ME2wMlAxOTVizszN	NWXLVGJXW0GQR1XS
ETK-1	M1qxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHRUJRKSzVyPUCuNFAyPTJizszN	NE\KeGxUSU6JRWK=
TE-10	NXTye3MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXqRoxbUUN3ME2wMlAxOTV2IN88US=>	M2nVVHNCVkeHUh?=
HUTU-80	M2TtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTiTWM2OD1yLkCwNVY5KM7:TR?=	M2HyfHNCVkeHUh?=
NTERA-S-cl-D1	NXu3N4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[3cGlEPTB;MD6wNFIxQSEQvF2=	MnTQV2FPT0WU
MFH-ino	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXFTWM2OD1yLkCwNlY5KM7:TR?=	NGfIW4ZUSU6JRWK=
IA-LM	NYrjeYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMECyPEDPxE1?	Mn3TV2FPT0WU
MC116	M{jmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXIeGdKSzVyPUCuNFAzQDlizszN	M1f1S3NCVkeHUh?=
RKO	NGjvTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vZUGlEPTB;MD6wNFI6QCEQvF2=	NIjUdIVUSU6JRWK=
MRK-nu-1	NYTKWZduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32xVGlEPTB;MD6wNFI6QSEQvF2=	M4m2e3NCVkeHUh?=
VA-ES-BJ	NEfYUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;YSnRKSzVyPUCuNFA{KM7:TR?=	NYKwN3pMW0GQR1XS
KALS-1	NFjGdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:2NGlEPTB;MD6wNFMxQCEQvF2=	M{DU[nNCVkeHUh?=
BB30-HNC	NX[wSW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn2TWM2OD1yLkCwN\|E1KM7:TR?=	MnP5V2FPT0WU
ACN	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfTTWM2OD1yLkCwN\|E3KM7:TR?=	M{K1XHNCVkeHUh?=
TE-9	M4mwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfKTWM2OD1yLkCwN\|I3KM7:TR?=	NVrtcHFpW0GQR1XS
SIG-M5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3hTWM2OD1yLkCwN\|I4KM7:TR?=	M{Hr[3NCVkeHUh?=
no-10	NVTGfpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nzXWlEPTB;MD6wNFM3OiEQvF2=	NEjoT5FUSU6JRWK=
EW-1	NY\Pdph1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHlN4ZFUUN3ME2wMlAxOzdzIN88US=>	NUTLWo82W0GQR1XS
SK-LMS-1	NYezOIttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHKTWM2OD1yLkCwOFAyKM7:TR?=	M{j2RnNCVkeHUh?=
GT3TKB	MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonXTWM2OD1yLkCwOFM1KM7:TR?=	MljkV2FPT0WU
ES4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHOTWM2OD1yLkCwOFQ6KM7:TR?=	M13MUHNCVkeHUh?=
IMR-5	M{\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHoTWM2OD1yLkCwOFUh\|ryP	NF;rdZVUSU6JRWK=
NCI-H1648	M3PhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rqW2lEPTB;MD6wNFQ3QSEQvF2=	NV7pXIQ{W0GQR1XS
MV-4-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEC0O\|Uh\|ryP	M1zoPXNCVkeHUh?=
SK-UT-1	NWjOV5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXWc5VEUUN3ME2wMlAxPDhizszN	NEDqUm5USU6JRWK=
NB13	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\v[mlEPTB;MD6wNFQ6OSEQvF2=	MYnTRW5ITVJ?
DJM-1	M1fkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEC1N{DPxE1?	MlfHV2FPT0WU
ES8	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXm4OWRpUUN3ME2wMlAxPTN6IN88US=>	MVHTRW5ITVJ?
TE-6	M2[xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnT6TWM2OD1yLkCwOVch\|ryP	M1m2fXNCVkeHUh?=
KS-1	NFG4U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlr4TWM2OD1yLkCwOVgzKM7:TR?=	NXvqTIRPW0GQR1XS
TE-1	M3vCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFyyd49KSzVyPUCuNFA3ODZizszN	MlXLV2FPT0WU
ATN-1	NUHFRYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMEC2NFkh\|ryP	MoTQV2FPT0WU
A4-Fuk	M3;admdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEC2NVEh\|ryP	M{XFRnNCVkeHUh?=
ALL-PO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELKXoNKSzVyPUCuNFA3OyEQvF2=	MVfTRW5ITVJ?
BE-13	NHmydGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\vUWlEPTB;MD6wNFY{PiEQvF2=	MnrwV2FPT0WU
KM12	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;qdIoxUUN3ME2wMlAxPjN5IN88US=>	NEjISm5USU6JRWK=
NOS-1	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXBTWM2OD1yLkCwOlUh\|ryP	MWPTRW5ITVJ?
SW962	NXP2PJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlf4TWM2OD1yLkCwOlYzKM7:TR?=	NXXvRoRzW0GQR1XS
OCUB-M	NIXlZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnUUYpKSzVyPUCuNFA3PjJizszN	NV3IW5hnW0GQR1XS
NCI-H510A	NUG0Rpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEC2OlUh\|ryP	NF22WG9USU6JRWK=
EW-16	M3\FRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzoVHBUUUN3ME2wMlAxPjl2IN88US=>	NWDzfoNbW0GQR1XS
KGN	NFW5OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjqTWM2OD1yLkCwO\|EzKM7:TR?=	MXLTRW5ITVJ?
LS-411N	Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfROZpIUUN3ME2wMlAxPzF5IN88US=>	Ml6wV2FPT0WU
Becker	NXXtcVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzBT3FKSzVyPUCuNFA4OiEQvF2=	MmjZV2FPT0WU
HC-1	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3p[HVQUUN3ME2wMlAxPzJzIN88US=>	MVjTRW5ITVJ?
CESS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEC3N\|ch\|ryP	MnfnV2FPT0WU
KURAMOCHI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvkNmhEUUN3ME2wMlAxPzR6IN88US=>	NWjiZ4J4W0GQR1XS
TGBC24TKB	NYTTWlVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3mSpZKSzVyPUCuNFA4PTJizszN	MXLTRW5ITVJ?
SW982	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLLNmxKSzVyPUCuNFA4PjZizszN	Mn7uV2FPT0WU
HCE-4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGe5PYxKSzVyPUCuNFA4PjdizszN	NF\hZZlUSU6JRWK=
LOUCY	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEC3O\|Uh\|ryP	M3PHO3NCVkeHUh?=
8-MG-BA	NUnRUVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEC3PVYh\|ryP	MY\TRW5ITVJ?
HT-144	NXzKeYliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPENVBKSzVyPUCuNFA5KM7:TR?=	MYXTRW5ITVJ?
LXF-289	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETZV\|JKSzVyPUCuNFA5OThizszN	MmS0V2FPT0WU
RS4-11	NFnJZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnSd2RKSzVyPUCuNFA5OzZizszN	NXnsc2JoW0GQR1XS
DEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDxb3RUUUN3ME2wMlAxQDR3IN88US=>	NFjjXXRUSU6JRWK=
OCI-AML2	NIj0fWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrZRVNmUUN3ME2wMlAxQDV{IN88US=>	NYX0So1PW0GQR1XS
CCRF-CEM	NFrzc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEC4O\|Eh\|ryP	NXi5bG1TW0GQR1XS
A388	M3r2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvSd5BNUUN3ME2wMlAxQDd2IN88US=>	MnvCV2FPT0WU
KNS-42	NInHWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDWTXNKSzVyPUCuNFA5QTFizszN	NHXHTmpUSU6JRWK=
OVCAR-4	NWLyTZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HRT2lEPTB;MD6wNFkxPCEQvF2=	MXPTRW5ITVJ?
NCI-H1355	NFzsVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMEC5NVQh\|ryP	MUDTRW5ITVJ?
BL-70	M2izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkL1TWM2OD1yLkCwPVMh\|ryP	NFrZNFFUSU6JRWK=
BL-41	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjsOmtKUUN3ME2wMlAxQTN2IN88US=>	M3zuTnNCVkeHUh?=
A101D	NIrRZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7jN5pKSzVyPUCuNFA6PiEQvF2=	M4rUZXNCVkeHUh?=
HL-60	NXXEN3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvTTWM2OD1yLkCwPVY3KM7:TR?=	MXvTRW5ITVJ?
COR-L279	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEC5PVkh\|ryP	M{TFeHNCVkeHUh?=
NCI-SNU-16	NEXiNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWntOJNqUUN3ME2wMlAyODB6IN88US=>	M1;DUXNCVkeHUh?=
Calu-6	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGSweG9KSzVyPUCuNFExOTJizszN	MV;TRW5ITVJ?
SR	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG0TWM2OD1yLkCxNFI3KM7:TR?=	NH7odnpUSU6JRWK=
QIMR-WIL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUK4dIIyUUN3ME2wMlAyODN\|IN88US=>	NH\ifHRUSU6JRWK=
LB647-SCLC	M3Xtemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnyfVhKSzVyPUCuNFExPTFizszN	MkLMV2FPT0WU
RPMI-8226	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj4S2tGUUN3ME2wMlAyOTB{IN88US=>	NIfRc4RUSU6JRWK=
SK-PN-DW	NUfXSIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTRTWM2OD1yLkCxNVEzKM7:TR?=	NX3DZlBHW0GQR1XS
SF268	NYjj[ldyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEGxOVEh\|ryP	NFjYcIVUSU6JRWK=
HD-MY-Z	NGjjbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P0[GlEPTB;MD6wNVE3OyEQvF2=	MV7TRW5ITVJ?
DOHH-2	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHPTWM2OD1yLkCxNlA{KM7:TR?=	NHmzS4ZUSU6JRWK=
SCC-3	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\STWM2OD1yLkCxNlA1KM7:TR?=	MkXVV2FPT0WU
ST486	NHHNOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMEGyNFQh\|ryP	M4f2VHNCVkeHUh?=
NALM-6	NGPR[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEGyNVQh\|ryP	M4n5fnNCVkeHUh?=
NCI-H1436	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvHTWM2OD1yLkCxNlMyKM7:TR?=	NYnSSVBFW0GQR1XS
KE-37	M13Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEGyN\|Qh\|ryP	MYXTRW5ITVJ?
RPMI-8402	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEGyOVYh\|ryP	M4DQWXNCVkeHUh?=
RXF393	NVHZR5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEGyOVch\|ryP	NGD2NYtUSU6JRWK=
KARPAS-45	M{Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfCTWM2OD1yLkCxNlch\|ryP	MlTTV2FPT0WU
HOP-62	M1rrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEGyO\|Yh\|ryP	NWTKc3FXW0GQR1XS
ES1	NV\EXnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjad4hQUUN3ME2wMlAyOjh6IN88US=>	Ml7mV2FPT0WU
L-363	NHzvcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDjTJRKSzVyPUCuNFE{PTFizszN	MWTTRW5ITVJ?
GI-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVixR5BjUUN3ME2wMlAyOzd\|IN88US=>	MV\TRW5ITVJ?
CTV-1	NVO3WpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXTS4ZKSzVyPUCuNFE1PzhizszN	Mkn3V2FPT0WU
TE-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMEG0PVYh\|ryP	Mly4V2FPT0WU
SNU-C2B	NIHKeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMEG0PVYh\|ryP	Mn\EV2FPT0WU
K-562	M{jEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTYemo{UUN3ME2wMlAyPTF4IN88US=>	NGX2dJFUSU6JRWK=
SNB75	M2XOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[xTmVkUUN3ME2wMlAyPTRizszN	M{KwPHNCVkeHUh?=
MOLT-13	NEfPfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonxTWM2OD1yLkCxOlM4KM7:TR?=	NF3IXIJUSU6JRWK=
LS-123	NHPkZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPrZ\|JPUUN3ME2wMlAyPjZ2IN88US=>	Mn7RV2FPT0WU
NCI-SNU-5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEG3NFEh\|ryP	NYjTNlRvW0GQR1XS
Daudi	NFrWPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml21TWM2OD1yLkCxO\|A5KM7:TR?=	NGLVT4tUSU6JRWK=
A253	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMEG3N\|gh\|ryP	M2G3e3NCVkeHUh?=
TGBC1TKB	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXMcolKSzVyPUCuNFE4PTJizszN	NISxU\|RUSU6JRWK=
SJSA-1	M{HKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HCSmlEPTB;MD6wNVc3PyEQvF2=	NYXh[5F1W0GQR1XS
NCCIT	M{\Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjBXIZ4UUN3ME2wMlAyPzZ7IN88US=>	NX;oU\|BFW0GQR1XS
NCI-H69	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HVeGlEPTB;MD6wNVc4QCEQvF2=	MVjTRW5ITVJ?
SH-4	M4TSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEG4PVUh\|ryP	M3nJc3NCVkeHUh?=
HCC1187	NYDGdnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMEG5NlQh\|ryP	MWHTRW5ITVJ?
HCC1599	NVrKeXRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHnfllKSzVyPUCuNFIxOiEQvF2=	NXy4cZBiW0GQR1XS
ONS-76	NF7VXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLaTWM2OD1yLkCyNFM3KM7:TR?=	M4LuWHNCVkeHUh?=
KU812	NE\pfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7kO45KSzVyPUCuNFIxOzlizszN	Ml3WV2FPT0WU
ML-2	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULBUW0yUUN3ME2wMlAzODR5IN88US=>	MkLJV2FPT0WU
HCE-T	NHPrUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;OTWM2OD1yLkCyNFkzKM7:TR?=	NGP2XGZUSU6JRWK=
NCI-H446	NUXVU3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXRTWM2OD1yLkCyNVEzKM7:TR?=	NI\VU4hUSU6JRWK=
RPMI-6666	NIf6WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPETWM2OD1yLkCyNVQ6KM7:TR?=	NIfqOGZUSU6JRWK=
MOLT-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXJTWM2OD1yLkCyNVU{KM7:TR?=	MYfTRW5ITVJ?
JiyoyeP-2003	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMEKxO\|Yh\|ryP	MVvTRW5ITVJ?
MHH-PREB-1	M2HiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml72TWM2OD1yLkCyNVkyKM7:TR?=	MnnVV2FPT0WU
MC-CAR	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEKzNlYh\|ryP	MYjTRW5ITVJ?
BC-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDWbm9[UUN3ME2wMlAzOzR2IN88US=>	NV3hfpl1W0GQR1XS
KINGS-1	NEHK[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITNOHdKSzVyPUCuNFI{PTVizszN	MXzTRW5ITVJ?
PF-382	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofWTWM2OD1yLkCyN\|c5KM7:TR?=	NFnnVGJUSU6JRWK=
J-RT3-T3-5	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T3[mlEPTB;MD6wNlM5OyEQvF2=	M4jpV3NCVkeHUh?=
SF539	M37mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEK0NFEh\|ryP	NVHpfIhIW0GQR1XS
LB831-BLC	M2K4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzlZ\|hKSzVyPUCuNFI1QDVizszN	MlHrV2FPT0WU
DMS-114	M{PkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\oT41KSzVyPUCuNFI2ODJizszN	M1\CTXNCVkeHUh?=
LB1047-RCC	M3PFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjrco9KSzVyPUCuNFI2OSEQvF2=	MUPTRW5ITVJ?
LB771-HNC	M1jPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrsXFBKSzVyPUCuNFI2OzRizszN	MWjTRW5ITVJ?
BB65-RCC	NF3W[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETQTmxKSzVyPUCuNFI2OzRizszN	NX3ld3RvW0GQR1XS
BV-173	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi3VWxKSzVyPUCuNFI2PTRizszN	MWfTRW5ITVJ?
ARH-77	M{P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y2T2lEPTB;MD6wNlYxOSEQvF2=	MUjTRW5ITVJ?
IST-MEL1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j4b2lEPTB;MD6wNlYzOyEQvF2=	MmTPV2FPT0WU
NB1	NIfBcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMEK2PFch\|ryP	MVLTRW5ITVJ?
EoL-1-cell	NYrIO\|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEK2PFgh\|ryP	MVzTRW5ITVJ?
KY821	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P2dWlEPTB;MD6wNlY6PyEQvF2=	M174WXNCVkeHUh?=
CMK	NFXoeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLuPFYxUUN3ME2wMlAzPzN2IN88US=>	NGrSSFNUSU6JRWK=
NCI-H2126	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzTTWM2OD1yLkCyO\|Y5KM7:TR?=	NXvmbm5vW0GQR1XS
NCI-H526	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMEK4PVEh\|ryP	M3THTnNCVkeHUh?=
COLO-684	M2LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\DTWM2OD1yLkCyPVA5KM7:TR?=	MmLoV2FPT0WU
NCI-H747	M4\UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXESnpKSzVyPUCuNFI6OzNizszN	NELve5hUSU6JRWK=
JAR	NULsO4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fWbmlEPTB;MD6wNlk1PiEQvF2=	MXzTRW5ITVJ?
MEG-01	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPtSpRUUUN3ME2wMlAzQTd6IN88US=>	M4HoXnNCVkeHUh?=
MONO-MAC-6	M1fkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfqUVdKSzVyPUCuNFMxOjNizszN	NIGwNZBUSU6JRWK=
IST-SL1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvTXmZEUUN3ME2wMlA{ODR{IN88US=>	MWTTRW5ITVJ?
CPC-N	NU\DTGpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfHNWpKSzVyPUCuNFMxPzlizszN	MW\TRW5ITVJ?
NCI-H1963	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7IfYxKSzVyPUCuNFMyOzFizszN	M{fX[XNCVkeHUh?=
K052	NEPG[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nOTGlEPTB;MD6wN\|I1PyEQvF2=	M4XVWHNCVkeHUh?=
KM-H2	M2q4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrTeYwzUUN3ME2wMlA{OzB5IN88US=>	NWfGcpo2W0GQR1XS
TE-12	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPQTWM2OD1yLkCzN\|A6KM7:TR?=	MW\TRW5ITVJ?
TK10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m4Z2lEPTB;MD6wN\|M2PiEQvF2=	NYfORohiW0GQR1XS
NMC-G1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrRO5hKSzVyPUCuNFM1PTJizszN	MV\TRW5ITVJ?
no-11	NVPXXm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMEO0O\|gh\|ryP	NV25flFIW0GQR1XS
NCI-H524	NHLkT\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMEO1Nlkh\|ryP	MVTTRW5ITVJ?
MHH-CALL-2	Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIf5clVKSzVyPUCuNFM2PjJizszN	NIHzfnRUSU6JRWK=
GB-1	M2D4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEO2JO69VQ>?	NEWyTJBUSU6JRWK=
OPM-2	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi3TWM2OD1yLkCzOlc{KM7:TR?=	M4fXeHNCVkeHUh?=
RH-1	M2rnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XRUGlEPTB;MD6wN\|gyQSEQvF2=	NXWzWmtzW0GQR1XS
NCI-H64	M1PEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMEO4OVch\|ryP	M1zLPHNCVkeHUh?=
EVSA-T	NX\XTog4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEO5NlMh\|ryP	MUDTRW5ITVJ?
KARPAS-299	NIL3Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIixZ2hKSzVyPUCuNFM6QCEQvF2=	NFLWU5JUSU6JRWK=
MZ7-mel	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMESwOEDPxE1?	M2nscnNCVkeHUh?=
LB373-MEL-D	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMESxNFUh\|ryP	NX;wVWRlW0GQR1XS
HEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[zTWM2OD1yLkC0NVQh\|ryP	M{TBdnNCVkeHUh?=
SW872	NFnqTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHhTWM2OD1yLkC0NlEh\|ryP	NX\HRW9yW0GQR1XS
DU-4475	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrCO4pKSzVyPUCuNFQzPDRizszN	Mk[4V2FPT0WU
IST-SL2	NEWzUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfqdXRKSzVyPUCuNFQzPzVizszN	MmHHV2FPT0WU
NCI-H82	NYK0bYVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH4ZnRKSzVyPUCuNFQ{ODdizszN	NIP4cGVUSU6JRWK=
LC4-1	M3PTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TQTWlEPTB;MD6wOFM2OSEQvF2=	MX\TRW5ITVJ?
HDLM-2	M3LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfsTWM2OD1yLkC0N\|kzKM7:TR?=	MkfzV2FPT0WU
MMAC-SF	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fVT2lEPTB;MD6wOFU{PCEQvF2=	NH;Gd3dUSU6JRWK=
L-540	NXLTU4lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln4TWM2OD1yLkC0OlM6KM7:TR?=	NWTSR3pzW0GQR1XS
MZ2-MEL	NWnUdYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzzW4tVUUN3ME2wMlA1PzR{IN88US=>	MUnTRW5ITVJ?
LU-134-A	NF7ZcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[2d\|lKSzVyPUCuNFQ4PzNizszN	NVLEXJJtW0GQR1XS
UACC-257	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\1NGlEPTB;MD6wOFg1QSEQvF2=	NXLOc4ZnW0GQR1XS
NCI-H1581	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLPNGZKSzVyPUCuNFQ6PTNizszN	NFHpWmhUSU6JRWK=
NB17	NFzhS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGxTWM2OD1yLkC0PVc6KM7:TR?=	MWrTRW5ITVJ?
SBC-1	NIjZbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PkcGlEPTB;MD6wOVA1OiEQvF2=	NFjrT5FUSU6JRWK=
TALL-1	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXOTWM2OD1yLkC1NFQ2KM7:TR?=	NVy4OmNrW0GQR1XS
NCI-H1304	NWDkXop6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEWyNFgh\|ryP	NWDtfIJUW0GQR1XS
NEC8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonYTWM2OD1yLkC1Nlg3KM7:TR?=	MlvvV2FPT0WU
CAL-148	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXSe4tKSzVyPUCuNFU1OzlizszN	NGfvc3lUSU6JRWK=
CGTH-W-1	NWDKO2ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjsTWM2OD1yLkC1OFQ6KM7:TR?=	M1zHPHNCVkeHUh?=
NCI-H889	NVfhfGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[yTWM2OD1yLkC1OVkzKM7:TR?=	NIHuU4xUSU6JRWK=
GR-ST	NGPtfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO3UXo{UUN3ME2wMlA2PjJzIN88US=>	NGLYOHZUSU6JRWK=
KARPAS-422	M3rsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPwbW1KSzVyPUCuNFU3PSEQvF2=	NIj0bIFUSU6JRWK=
RPMI-8866	NFTyWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XhVWlEPTB;MD6wOVcyOiEQvF2=	NGnZdndUSU6JRWK=
SCLC-21H	Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jnfmlEPTB;MD6wOVg5PCEQvF2=	M2roZ3NCVkeHUh?=
COR-L88	M{TMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvNTWM2OD1yLkC1PVI4KM7:TR?=	MWHTRW5ITVJ?
LU-139	NFXQZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1r3SmlEPTB;MD6wOVk5PiEQvF2=	NELjXVBUSU6JRWK=
SF126	NEjBS\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrN[HVKSzVyPUCuNFYyOzNizszN	M1TwcXNCVkeHUh?=
NCI-H1882	NEDvSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTUTWM2OD1yLkC2OFI1KM7:TR?=	M{jIVHNCVkeHUh?=
EW-24	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLNdG9KSzVyPUCuNFY1QDNizszN	NXfsWoE1W0GQR1XS
CP67-MEL	NVviTZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;5d5lbUUN3ME2wMlA3QDFizszN	M16xZnNCVkeHUh?=
DG-75	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonUTWM2OD1yLkC2PFk6KM7:TR?=	NHTD[ZZUSU6JRWK=
LOXIMVI	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPGSJo5UUN3ME2wMlA4ODJ6IN88US=>	NX7mVZl5W0GQR1XS
HH	NH7McFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj5cXRwUUN3ME2wMlA4OTV5IN88US=>	M3zLW3NCVkeHUh?=
K5	NYHmcJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojmTWM2OD1yLkC3NlI3KM7:TR?=	NWi3e3lmW0GQR1XS
EC-GI-10	M4P4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMEeyOVch\|ryP	MoryV2FPT0WU
SK-N-DZ	NVX0NIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\wfJBKSzVyPUCuNFc{ODdizszN	NXXJUIllW0GQR1XS
A3-KAW	NU[5PHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\3TWM2OD1yLkC3N\|UyKM7:TR?=	MUDTRW5ITVJ?
MLMA	NHX0eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj2TWM2OD1yLkC3OFY2KM7:TR?=	MmLpV2FPT0WU
LB996-RCC	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrBPI96UUN3ME2wMlA4PzB5IN88US=>	MWXTRW5ITVJ?
OS-RC-2	NInrS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHXTmlKSzVyPUCuNFc4PDhizszN	MWDTRW5ITVJ?
CTB-1	NGH6UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\pU5hKSzVyPUCuNFc5OSEQvF2=	MmfwV2FPT0WU
IST-MES1	M2\t[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfNTWM2OD1yLkC3PVEzKM7:TR?=	NHriWJVUSU6JRWK=
LS-1034	M2PZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPvc4p[UUN3ME2wMlA5ODN3IN88US=>	NEPifoFUSU6JRWK=
HT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPjU41tUUN3ME2wMlA5ODh4IN88US=>	M2mwS3NCVkeHUh?=
NCI-H2141	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7xT3VKSzVyPUCuNFgyKM7:TR?=	NGrJPYFUSU6JRWK=
LB2518-MEL	NVOyb3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfLWlFEUUN3ME2wMlA5OTRzIN88US=>	NE[4NXZUSU6JRWK=
GI-ME-N	M1zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LU[2lEPTB;MD6wPFQ2OiEQvF2=	MnLXV2FPT0WU
TGW	NF;OZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XUcGlEPTB;MD6wPFYxPyEQvF2=	NEH4NFlUSU6JRWK=
SK-NEP-1	M3XJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvWZ416UUN3ME2wMlA5PjRzIN88US=>	NHfCR5hUSU6JRWK=
NOMO-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTWTWM2OD1yLkC5Nlc2KM7:TR?=	M2DVWnNCVkeHUh?=
ES6	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMEm1PFkh\|ryP	NGO0TZlUSU6JRWK=
NCI-H209	MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DwRmlEPTB;MD6wPVc5PiEQvF2=	M3HZbXNCVkeHUh?=
GAK	NFzj[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkOyTWM2OD1yLkGwNVYh\|ryP	MYnTRW5ITVJ?
BC-1	NXKwV2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HxXmlEPTB;MD6xNFM3OSEQvF2=	MX3TRW5ITVJ?
KLE	NHXpc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\3TWM2OD1yLkGwOFQ{KM7:TR?=	MUDTRW5ITVJ?
EW-3	NUfrTI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1r6VmlEPTB;MD6xNFk5KM7:TR?=	NF[0TY5USU6JRWK=
NKM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMUGxJO69VQ>?	NG\ZTlVUSU6JRWK=
D-336MG	NUTuNGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjzdWhsUUN3ME2wMlEyOjR2IN88US=>	MkX1V2FPT0WU
NB69	NVK0bVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\6ZVJKSzVyPUCuNVE{ODFizszN	NVfaXo9ZW0GQR1XS
D-263MG	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUG3NVIh\|ryP	MmfVV2FPT0WU
KP-N-YS	M4WwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMUKyPVEh\|ryP	MWrTRW5ITVJ?
NCI-H1155	M2HKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\kcHRKSzVyPUCuNVI2PThizszN	M2fmenNCVkeHUh?=
BOKU	NI[1NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3j5PGlEPTB;MD6xNlU4QSEQvF2=	Mli5V2FPT0WU
LAMA-84	NWThU4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTSTWM2OD1yLkGyPVkh\|ryP	M4O2[HNCVkeHUh?=
Raji	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\EemlEPTB;MD6xN\|EyPyEQvF2=	NECy[GdUSU6JRWK=
LU-65	M324OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjlTWM2OD1yLkGzN\|A4KM7:TR?=	MYnTRW5ITVJ?
NCI-H187	NVnVcG9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVKzPItHUUN3ME2wMlE{QTJ2IN88US=>	NXPGdlV[W0GQR1XS
GCIY	NXLHbJduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;2OGlEPTB;MD6xOFkxOSEQvF2=	MXnTRW5ITVJ?
NCI-H2107	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfTTWM2OD1yLkG1NFgh\|ryP	MmnSV2FPT0WU
NCI-H1522	M17tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3wTWM2OD1yLkG1NlY3KM7:TR?=	MUnTRW5ITVJ?
NB6	NYXqXYt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf5XmlIUUN3ME2wMlE2PjJ\|IN88US=>	NH3ZPWtUSU6JRWK=
EM-2	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMUW3NFYh\|ryP	NFvqSoZUSU6JRWK=
HCC2218	M1juT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTHUFdKSzVyPUCuNVU6QCEQvF2=	MmW1V2FPT0WU
NCI-H748	NYPmSlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TSRWlEPTB;MD6xOlM4PiEQvF2=	NI[xSJlUSU6JRWK=
MS-1	M1GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2yOFBKSzVyPUCuNVY2OzdizszN	MUPTRW5ITVJ?
NB5	M336Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjTd3d4UUN3ME2wMlE3PTl5IN88US=>	Ml3MV2FPT0WU
OMC-1	NIjRToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGmyemJKSzVyPUCuNVY3QDhizszN	M1rqW3NCVkeHUh?=
NCI-H345	M37hfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3NfIZtUUN3ME2wMlE3QTJ6IN88US=>	M{f6RnNCVkeHUh?=
L-428	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;EU3RKSzVyPUCuNVY6PDVizszN	MlPFV2FPT0WU
SCH	NGC5cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnuwTWM2OD1yLkG4Olg2KM7:TR?=	NEmyOoxUSU6JRWK=
NCI-H1417	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfoXYtKSzVyPUCuNVkzOjdizszN	NHrEb4dUSU6JRWK=
COLO-320-HSR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXNTWM2OD1yLkG5OVMzKM7:TR?=	NWDvWVhHW0GQR1XS
BT-474	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMkC4PVIh\|ryP	M2nnSXNCVkeHUh?=
GDM-1	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LCN2lEPTB;MD6yNVk4OSEQvF2=	MXHTRW5ITVJ?
NCI-H2196	NXXMZWdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW1TWM2OD1yLkKyNlM2KM7:TR?=	MlXyV2FPT0WU
KP-N-RT-BM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHpRoVKSzVyPUCuNlI{PDlizszN	M4GzWHNCVkeHUh?=
KNS-81-FD	NFL1SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X5[mlEPTB;MD6yNlk2QCEQvF2=	MWrTRW5ITVJ?
COLO-668	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTrW5lKSzVyPUCuNlM3PzVizszN	NV2zSndZW0GQR1XS
C2BBe1	M3XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMk[3OFch\|ryP	M1rCPXNCVkeHUh?=
Ramos-2G6-4C10	NH7aVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMk[5OVQh\|ryP	NWP4emhXW0GQR1XS
CAS-1	NU\YVop3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NESxXIlKSzVyPUCuNlcxQTZizszN	MVLTRW5ITVJ?
GOTO	M4fGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jWTGlEPTB;MD6yO\|g6PCEQvF2=	NYO4N482W0GQR1XS
LP-1	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHETXh7UUN3ME2wMlI5ODV5IN88US=>	MomwV2FPT0WU
NCI-SNU-1	NGPlVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWCyS3dPUUN3ME2wMlI6PDJ{IN88US=>	M4Lrb3NCVkeHUh?=
EB-3	NED0fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMkm5O\|kh\|ryP	NV;4cmN7W0GQR1XS
MHH-NB-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwM{C0NFIh\|ryP	MWPTRW5ITVJ?
SK-N-FI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X6dGlEPTB;MD6zNVY6OiEQvF2=	MVXTRW5ITVJ?
HCC2157	NXTVV41jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\pTWM2OD1yLkOzPVE{KM7:TR?=	MU\TRW5ITVJ?
SIMA	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwM{S1PFEh\|ryP	NX3kOI97W0GQR1XS
MDA-MB-134-VI	NVL3T\|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jWOmlEPTB;MD6zOlkzQCEQvF2=	NGLuVXZUSU6JRWK=
NCI-H1694	NYfk[phpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF6ze\|JKSzVyPUCuN\|ch\|ryP	NFHGcINUSU6JRWK=
EHEB	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwM{mwPFUh\|ryP	MmrXV2FPT0WU
U-266	M4TGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwM{m4OFYh\|ryP	MX7TRW5ITVJ?
LC-1F	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DDe2lEPTB;MD60N\|c3PSEQvF2=	MorMV2FPT0WU
SHP-77	NH\aOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4X3TGlEPTB;MD60O\|g2PSEQvF2=	NE[3OnZUSU6JRWK=
LS-513	Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPoNIRmUUN3ME2wMlQ6OzB5IN88US=>	M2rvNHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[4]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 57 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 57 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)